Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Director of scientific R&D firm fined $195K+ over biogas experiments
The fine follows a 2022 incident in which a doctor sustained serious injuries after exposure to...
7th edition of STEM Equity Monitor now available
The latest national data resource on diversity in STEM has new design features intended to...
Professor Girish Dwivedi wins 2026 WA Pearcey Entrepreneur of the Year Award
As part of the 35th annual WAITTA INCITE Awards, Dwivedi was recognised for his contribution to...
